Aligos Therapeutics Inc. has disclosed programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment ...
Hosted on MSN2mon
Dr Reddy’s launches world's 1st immuno-onco drug for nasopharyngeal cancer in IndiaToripalimab is a new biological entity (NBE) that has the ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2 and promotes ... next generation PD-1 inhibitor, Toripalimab has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback